In people who have antibodies indicating early risk for type 1 diabetes but still have normal blood sugar, a decrease in the hormone GIP—compared to GLP-1—appears to be the main reason for reduced...

People who have multiple autoantibodies targeting their pancreatic islets but still have normal blood sugar levels show a 45% decrease in the hormone response that helps regulate insulin after eating, along with lower levels of the GIP hormone during a glucose test, indicating early metabolic changes before diabetes develops.

People who have multiple autoantibodies related to type 1 diabetes but still have normal blood sugar levels show lower levels of the hormone GIP after consuming glucose, compared to those with only one such autoantibody. This difference may reflect an early disruption in the hormonal pathway that helps stimulate insulin release.

In female mice, removing receptors for GIP and GLP-1 hormones does not stop the pancreas from releasing insulin when glucose is injected into the bloodstream, showing that the pancreas can still detect glucose levels even without these hormonal signals.

People who have multiple autoantibodies targeting their pancreatic islets, but still maintain normal blood sugar levels, show a smaller insulin response to oral glucose compared to intravenous glucose, suggesting an early alteration in how the gut and pancreas communicate.

In female mice, removing receptors for two gut hormones reduces the pancreas's ability to release insulin in response to sugar taken by mouth, but not when sugar is injected directly into the bloodstream, showing that these hormones help the pancreas respond to food entering the gut.